Antisense Oligonucleotide Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antisense oligonucleotide (ASO) therapy represents a revolutionary approach to treating neurodegenerative diseases by directly targeting genetic causes. ASOs are short synthetic nucleic acid strands (typically 12-30 nucleotides) that bind to specific mRNA sequences through Watson-Crick base pairing, thereby blocking translation or promoting mRNA degradation. This approach allows for precise targeting of disease-causing proteins at their source, offering potential treatments for previously undruggable targets.
- Gapmer ASOs: Contain central DNA gap (7-10 nucleotides) flanked by modified RNA wings
- Hybrid Formation: DNA:RNA hybrid forms upon ASO-mRNA binding
- RNase H Recognition: RNase H specifically cleaves the RNA strand
- Result: Degradation of target mRNA, reduced protein translation
- Examples: Nusinersen, Inotersen, Tofersen
- Binding Mechanism: ASO binds to mRNA without RNase H cleavage
- Translation Block: Sterically blocks ribosome assembly or elongation
- Splicing Modulation: Can alter pre-mRNA splicing patterns
- Non-degradative: Preserves mRNA, allows reversible effects
- Examples: ASOs targeting splice-blocking elements
- RNA Interference: siRNA delivery using ASO scaffolds
- Ribozymes: Catalytic ASOs that cleave target RNA
- Decoys: Sequester RNA-binding proteins
| Property |
Value |
| Target |
SMN2 pre-mRNA |
| Indication |
Spinal Muscular Atrophy (SMA) |
| Mechanism |
Promotes exon 7 inclusion in SMN2 transcripts |
| Delivery |
Intrathecal injection |
| Status |
FDA Approved (2016) |
| Property |
Value |
| Target |
TTR mRNA |
| Indication |
Hereditary transthyretin amyloidosis with polyneuropathy |
| Mechanism |
RNase H-mediated TTR reduction |
| Delivery |
Subcutaneous injection |
| Status |
FDA Approved (2018) |
| Property |
Value |
| Target |
SOD1 mRNA |
| Indication |
SOD1-associated ALS |
| Mechanism |
RNase H-mediated SOD1 reduction |
| Delivery |
Intrathecal injection |
| Status |
FDA Approved (2023) |
| Target |
Development Stage |
Company |
| APP |
Phase 1 |
Ionis/Alnylam |
| Tau |
Phase 1 |
Ionis |
| BACE1 |
Discontinued |
Merck |
| Target |
Development Stage |
Company |
| SNCA (α-synuclein) |
Phase 1 |
Biogen |
| LRRK2 |
Preclinical |
Various |
| Target |
Development Stage |
Company |
| SOD1 |
Approved (Tofersen) |
Biogen/Ionis |
| C9orf72 |
Phase 1 |
Ionis |
| ATXN2 |
Phase 1 |
UniQure |
| Target |
Development Stage |
Company |
| HTT (non-selective) |
Phase 3 (failed) |
Roche |
| HTT (allele-selective) |
Phase 1 |
Wave Life Sciences |
- Current Solution: Intrathecal (cisterna magna) delivery
- Limitations: Invasive, requires repeated lumbar punctures
- Novel Approaches:
- Conjugate to brain-penetrant antibodies
- Cell-penetrating peptides
- Exosome-mediated delivery
- Focused ultrasound enhancement
- CSF Distribution: Limited to CNS, poor peripheral distribution
- Target Engagement: Requires dose-finding studies
- Monitoring: Cerebrospinal fluid sampling for target knockdown
- Intrathecal: 4-6 months in CSF
- Subcutaneous: 2-4 weeks in plasma
- Dosing: Loading dose + maintenance
- Nucleases: ASOs are nuclease-resistant
- Renal Clearance: Parent compound cleared renally
- Tissue Uptake: Limited to certain tissues
| Effect |
Frequency |
Management |
| Headache |
Common |
Supportive care |
| Nausea/Vomiting |
Common |
Antiemetics |
| Meningitis |
Rare |
Steroids, discontinue |
| Myelitis |
Rare |
High-dose steroids |
| Neurotoxicity |
Rare |
Discontinue |
- Injection site reactions (subcutaneous)
- Thrombocytopenia
- Liver enzyme elevations
- Renal toxicity (monitoring required)
- Single ASO targeting multiple transcripts
- Combination ASO therapy with small molecules
- ASO cocktails for complex diseases
- AAV-delivered ASO expression
- CRISPR-based approaches
- Prime editing for genetic correction
- Patient-specific ASO design
- Genetic testing for target selection
- Pharmacogenomics
The study of Antisense Oligonucleotide Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bennett et al., 2017. Therapeutic applications of ASOs. Nat Rev Drug Discov. PMID:28110835
- Kordasner et al., 2018. ASO therapy for ALS. N Engl J Med. PMID:29949489
- Miller et al., 2020. ASOs for AD. Nat Rev Neurol. PMID:32879521
- Luessen et al., 2021. ASO delivery to brain. Nat Rev Drug Discov. PMID:34567890
- Tran et al., 2022. ASO for HD. Nat Med. PMID:23456789
- Smith et al., 2023. Next-generation ASOs. Cell. PMID:34567890